Bertrand Delsuc: Refreshed Breast Cancer Map
Bertrand Delsuc, CEO and Founder at Biotellytics, shared a post on X:
“Daiichi Sankyo AZN refreshed Breast Cancer Map.
Next readouts:
- TB-02 1L TNBC before the end of March 2025
- DB-11 neoadjuvant HER2+ before the end of September 2025
- DB-05 (adj HER2+) and DB-09 (1L HER2+) before the end of March 2026.”
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared this post, adding:
“Multiple practice changes expected over the next two years.”
More posts featuring Bertrand Delsuc and Paolo Tarantino
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023